A preliminary experience of moderate-intensity stereotactic body radiation therapy for ultra-central lung tumor

Sunmin Park, Young Kim, Won Sup Yoon, Chai Hong Rim

Research output: Contribution to journalArticle

Abstract

Purpose: Administration of stereotactic body radiation therapy (SBRT) to ultra-central (UC) lung tumors, generally defined as those abutting the proximal bronchial trees, is difficult due to concerns about serious toxicities. Therefore, our institution has performed moderate-intensity SBRT. Patients and methods: Patients with UC tumors underwent SBRT at a dose of 50–60 Gy in 10 fractions, with Dmax in the target volume not exceeding 110% of the prescribed dose. The primary outcomes were tumor response and overall survival (OS). Results: From January 2017 to September 2018, we treated eight patients who had been diagnosed with UC tumors. The median follow-up time was 8.6 months (range: 2.7–14.9). Five of the eight patients (62.5%) showed a complete response (CR), two (25%) had a partial response (PR), and one (12.5%) had stable disease (SD); the response and disease control rates were 87.5% and 100%, respectively. Seven patients were alive with no evidence of disease or with controlled disease until the last follow-ups, except for one patient who died due to a non-RT cause at 3 months after SBRT. One patient experienced grade 2 esophageal pain and another had grade 1 cough. No grade 3 or higher toxicities were reported. Conclusion: Moderate-intensity SBRT might aid in achieving good control of UC tumors without excessive toxicities. Future studies involving larger numbers of patients and longer follow-up times are warranted to confirm the efficacy and feasibility.

Original languageEnglish
JournalInternational Journal of Radiation Biology
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Radiotherapy
Lung
Neoplasms
Cough
Pain
Survival

Keywords

  • feasibility
  • radiotherapy
  • Stereotactic body radiotherapy
  • ultra-central tumor

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging

Cite this

A preliminary experience of moderate-intensity stereotactic body radiation therapy for ultra-central lung tumor. / Park, Sunmin; Kim, Young; Yoon, Won Sup; Rim, Chai Hong.

In: International Journal of Radiation Biology, 01.01.2019.

Research output: Contribution to journalArticle

@article{d4de6813ac6d43879b9c4c61f2a2779d,
title = "A preliminary experience of moderate-intensity stereotactic body radiation therapy for ultra-central lung tumor",
abstract = "Purpose: Administration of stereotactic body radiation therapy (SBRT) to ultra-central (UC) lung tumors, generally defined as those abutting the proximal bronchial trees, is difficult due to concerns about serious toxicities. Therefore, our institution has performed moderate-intensity SBRT. Patients and methods: Patients with UC tumors underwent SBRT at a dose of 50–60 Gy in 10 fractions, with Dmax in the target volume not exceeding 110{\%} of the prescribed dose. The primary outcomes were tumor response and overall survival (OS). Results: From January 2017 to September 2018, we treated eight patients who had been diagnosed with UC tumors. The median follow-up time was 8.6 months (range: 2.7–14.9). Five of the eight patients (62.5{\%}) showed a complete response (CR), two (25{\%}) had a partial response (PR), and one (12.5{\%}) had stable disease (SD); the response and disease control rates were 87.5{\%} and 100{\%}, respectively. Seven patients were alive with no evidence of disease or with controlled disease until the last follow-ups, except for one patient who died due to a non-RT cause at 3 months after SBRT. One patient experienced grade 2 esophageal pain and another had grade 1 cough. No grade 3 or higher toxicities were reported. Conclusion: Moderate-intensity SBRT might aid in achieving good control of UC tumors without excessive toxicities. Future studies involving larger numbers of patients and longer follow-up times are warranted to confirm the efficacy and feasibility.",
keywords = "feasibility, radiotherapy, Stereotactic body radiotherapy, ultra-central tumor",
author = "Sunmin Park and Young Kim and Yoon, {Won Sup} and Rim, {Chai Hong}",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/09553002.2019.1626026",
language = "English",
journal = "International Journal of Radiation Biology",
issn = "0955-3002",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - A preliminary experience of moderate-intensity stereotactic body radiation therapy for ultra-central lung tumor

AU - Park, Sunmin

AU - Kim, Young

AU - Yoon, Won Sup

AU - Rim, Chai Hong

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: Administration of stereotactic body radiation therapy (SBRT) to ultra-central (UC) lung tumors, generally defined as those abutting the proximal bronchial trees, is difficult due to concerns about serious toxicities. Therefore, our institution has performed moderate-intensity SBRT. Patients and methods: Patients with UC tumors underwent SBRT at a dose of 50–60 Gy in 10 fractions, with Dmax in the target volume not exceeding 110% of the prescribed dose. The primary outcomes were tumor response and overall survival (OS). Results: From January 2017 to September 2018, we treated eight patients who had been diagnosed with UC tumors. The median follow-up time was 8.6 months (range: 2.7–14.9). Five of the eight patients (62.5%) showed a complete response (CR), two (25%) had a partial response (PR), and one (12.5%) had stable disease (SD); the response and disease control rates were 87.5% and 100%, respectively. Seven patients were alive with no evidence of disease or with controlled disease until the last follow-ups, except for one patient who died due to a non-RT cause at 3 months after SBRT. One patient experienced grade 2 esophageal pain and another had grade 1 cough. No grade 3 or higher toxicities were reported. Conclusion: Moderate-intensity SBRT might aid in achieving good control of UC tumors without excessive toxicities. Future studies involving larger numbers of patients and longer follow-up times are warranted to confirm the efficacy and feasibility.

AB - Purpose: Administration of stereotactic body radiation therapy (SBRT) to ultra-central (UC) lung tumors, generally defined as those abutting the proximal bronchial trees, is difficult due to concerns about serious toxicities. Therefore, our institution has performed moderate-intensity SBRT. Patients and methods: Patients with UC tumors underwent SBRT at a dose of 50–60 Gy in 10 fractions, with Dmax in the target volume not exceeding 110% of the prescribed dose. The primary outcomes were tumor response and overall survival (OS). Results: From January 2017 to September 2018, we treated eight patients who had been diagnosed with UC tumors. The median follow-up time was 8.6 months (range: 2.7–14.9). Five of the eight patients (62.5%) showed a complete response (CR), two (25%) had a partial response (PR), and one (12.5%) had stable disease (SD); the response and disease control rates were 87.5% and 100%, respectively. Seven patients were alive with no evidence of disease or with controlled disease until the last follow-ups, except for one patient who died due to a non-RT cause at 3 months after SBRT. One patient experienced grade 2 esophageal pain and another had grade 1 cough. No grade 3 or higher toxicities were reported. Conclusion: Moderate-intensity SBRT might aid in achieving good control of UC tumors without excessive toxicities. Future studies involving larger numbers of patients and longer follow-up times are warranted to confirm the efficacy and feasibility.

KW - feasibility

KW - radiotherapy

KW - Stereotactic body radiotherapy

KW - ultra-central tumor

UR - http://www.scopus.com/inward/record.url?scp=85067576458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067576458&partnerID=8YFLogxK

U2 - 10.1080/09553002.2019.1626026

DO - 10.1080/09553002.2019.1626026

M3 - Article

JO - International Journal of Radiation Biology

JF - International Journal of Radiation Biology

SN - 0955-3002

ER -